NEW YORK (Reuters) – The Johnson & Johnson COVID-19 single-dose vaccine received approval from the U.S. on Saturday and will begin delivery to Americans within days.
The following is how it responds to the vaccination effort by the other two authorized vaccines from Pfizer Inc / BioNTech SE and Moderna Inc.
IS J&J VACCINE AS EFFECTIVE AS THE OTHER TWO?
The Pfizer / BioNTech and Moderna vaccines, both of which use new messenger RNA technology, showed around 95% efficacy in preventing illness in large trials, while J&J showed efficacy around air 66%.
However, there were important differences in the experiments, making comparisons difficult. Pfizer and Moderna focused on efficacy against moderate-to-severe illness, while the J&J trial looked for efficacy against moderate-to-severe COVID-19.
The J&J lawsuit was later made and involved large numbers of participants in regions where new variants of the highly malignant virus were circulating, and that could go through a tougher test.
Importantly, the J&J vaccine was as effective against serious illness and hospitalization as the other vaccines and, like the others, was 100% effective in preventing COVID-19-related deaths in the test.
All three vaccines have the same type of short-term effects, including muscle weakness, pain, injection site pain, nausea and fever, usually moderate-to-severe.
IF J & JA’S INVOLVED, WHY ARE WE INVOLVED?
The J & J vaccine is one picture. Each Pfizer / BioNTech and Moderna vaccine requires two pictures three or four weeks apart.
J&J bullet is extremely effective in preventing people exposed to COVID-19 from becoming seriously ill or dying, as well as offering protection against more serious cases. quiet.
“These vaccines are the way to get your life back on track,” said Amesh Adalja, a senior scholar at the Johns Hopkins Center for Health Security. “These are vaccines that you should not delay when they are offered to you.”
The J&J vaccine is one of the few that has been tested in clinical pathways against the anxiety virus that was first discovered in South Africa. It showed the ability to provide protection from serious disease and death even for those infected with that variant. Pfizer and Moderna have only tested their vaccines against laboratory variants and believe they will remain immune.
DO I HAVE A TEAR OF VACCINE?
Experts say a vaccine supply for the next month or two will be too scarce for healthcare providers to offer a choice. Most vaccine sites will only receive one of three vaccines at a given time.
Patients who prefer a particular vaccine can ask healthcare providers which one they have available. Later in the year, more shots may become available as a result of more patient choice, but health experts strongly advise no matter what vaccine you receive.
HOW GOOD ARE DOSES ON A NEW SHOT J & JA WILL GET?
J&J said it plans to dispose of nearly 4 million doses in the first week, and shipments could start late Sunday or early Monday.
J&J plans to deliver 20 million views by the end of March and as many as 100 million doses by mid-year.
The federal government, through distributor McKesson Corp., sends J&J photos to states and regions around the United States. It will also deliver them to select pharmacies and community health centers to ensure they reach inadequate numbers.
Between J&J, Pfizer / BioNTech and Moderna, the United States is on track to receive 240 million doses by the end of March, enough to fully absorb 130 million Americans. The drug dealers have agreed to send 700 million doses of their vaccines by the end of July, more than enough for all Americans to be vaccinated.
Reporting by Michael Erman and Carl O’Donnell; Edited by Peter Henderson and Bill Berkrot